YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Medicus Pharma Ltd Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient Development PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a…
Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage CD228-targeting antibody-drug conjugate. The agreement grants Medicus exclusive global rights to develop and commercialize the C…
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss a transformative agreement with Pfizer that significantly strengthens the company's position in precision oncology and provides key resources to advance its…
(RTTNews) - Medicus Pharma Ltd. (MDCX) announced that the Department of Health (DOH) - Abu Dhabi has granted Investigational New Drug (IND) authorization, for the Phase 2a PRECISION-E2 genomics-enabled trial to evaluate Teverelix in women…
(RTTNews) - Medicus Pharma Inc. (MDCX), a biotech/life sciences company, on Tuesday announced the receipt of a 'Study May Proceed' notification from the U.S. Food and Drug Administration (FDA), allowing for the initiation of the Phase 2b S…
PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive the…
PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive the…
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Medicus Pharma Ltd. (NASDAQ:MDCX) is one of the best low-priced pharma stocks on this list. TheFly reported on June 15 that MDCX announced the filing of…
PHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive the…
(RTTNews) - Medicus Pharma Ltd. (MDCX) on Monday announced the submission of a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration for SkinJect for the treatment of basal cell carcinoma in patients wi…
PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive the…
PHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive the…
4:15pm: Chipmakers fuel Wall Street rebound The stock market managed to claw back some ground on Monday, with technology shares leading the rebound after last week's sharp selloff. The Nasdaq rose 221 points, or 0.9%, to close at 25,930, w…
4:20pm: Investors dial back risk Stocks pulled back on Wednesday, retreating from record highs as fading hopes for a quick diplomatic breakthrough between the United States and Iran prompted investors to take some risk off the table. The D…
(RTTNews) - Medicus Pharma Ltd (MDCX), a biotech/life sciences company, on Friday reported entering into a definitive financing agreement. The company reportedly signed the agreement with an institutional investor for $22 million in a stru…
Medicus Pharma (NASDAQ:MDCX) announced on Thursday that it has entered into a definitive financing agreement with an institutional investor for an up to $22 million structured, non-dilutive financing facility aimed at supporting its clinic…
We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Medicus Pharma Ltd. (NASDAQ:MDCXW) is one of the best penny stocks on this list. TheFly reported on May 14 that MDCXW announced its financial result…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Medicus Pharma Ltd. on Wednesday reported expanded Phase 2 SKNJCT-003 study data showing a clear dose-response relationship for its Doxoru…
Nasdaq, S&P 500 close at all-time highs on strong AI momentum Proactive uses images sourced from Shutterstock 4:15pm: Chip stocks lead rally Both the S&P 500 and Nasdaq set new all-time closing highs, as US stocks extended their rally on s…
PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive ther…
S&P 500 and Nasdaq close at fresh records as tech leads quiet advance Proactive uses images sourced from Shutterstock 4:20pm: Tech keeps momentum intact Wall Street finished the session on a quietly constructive note, with the major benchm…
(RTTNews) - Medicus Pharma Ltd. (MDCX), a clinical-stage biopharmaceutical company, announced that it has submitted an optimized Phase 2 study protocol to the U.S. FDA for Teverelix, its lead candidate in the treatment of acute urinary ret…
PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive th…
PHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive th…
PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive th…
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.…
PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive th…
PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive th…
PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of no…
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix®as a first in class market product for Acute Urinary Retention Relapse preven…
Medicus Pharma Ltd The Company enters 2026 with Multiple Phase 2 Catalysts, AI-enabled drug development strategy, and regulatory optionality as SKNJCT-003 study approaches database lock, topline clinical data readout and partnering readine…
(RTTNews) - Medicus Pharma Ltd. (MDCX), a biotech company, Monday announced that its President Carolyn Bonner, has also been appointed as its chief financial officer. Bonner had been the acting Chief Financial Officer since September 12 in…
PHILADELPHIA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potential…
Medicus Pharma Ltd (NASDAQ:MDCX) is one of the Canadian penny stocks to buy right now. On November 18, Maxim Group analyst Jason McCarthy maintained a Buy rating on Medicus Pharma Ltd (NASDAQ:MDCX) with a $20 price target, citing the compa…
PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially prostate and skin cancer, which ar…
PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive the…